ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has tumbled 10.36% during the past week and has dropped 17.73% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 9.28%. ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has underperformed the index by 18.48% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP): The stock opened at $6.26 on Friday but the bulls could not build on the opening and the stock topped out at $6.32 for the day. The stock traded down to $5.79 during the day, due to lack of any buying support eventually closed down at $5.80 with a loss of -6.90% for the day. The stock had closed at $6.23 on the previous day. The total traded volume was 3,780,912 shares.
The company shares have dropped -53.60% from its 1 Year high price. On Nov 10, 2015, the shares registered one year high at $14.93 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $7.07 and the 200 Day Moving Average price is recorded at $7.50.
On the companys insider trading activities,The officer (COO, CLO, and Secretary) of Ziopharm Oncology Inc, Belbel Caesar J sold 153,333 shares at $12.84 on November 19, 2015. The Insider selling transaction had a total value worth of $1,968,796. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Many analysts have stated their opinion on the company shares. Raymond James initiates coverage on ZIOPHARM Oncology Inc (NASDAQ:ZIOP) The current rating of the shares is Market Perform. The rating by the firm was issued on June 2, 2016. Currently the company Insiders own 18.2% of ZIOPHARM Oncology Inc shares according to the proxy statements. Institutional Investors own 42.42% of ZIOPHARM Oncology Inc shares.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).